Literature DB >> 14992306

Electroconvulsive therapy for affective disorders in persons with mental retardation.

Richard J Kessler1.   

Abstract

Despite the efficacy of electroconvulsive therapy for the treatment of affective disorders there are no systematic studies of its effectiveness or safety in the mentally retarded population. A literature search revealed 16 case reports that suggests that it is both as effective and safe with mentally retarded persons as in the general population. Four additional clinical vignettes, with extensive follow-up observation from four to eleven years, are presented in an effort to enrich the literature on this subject. They include patients with rapid cycling bipolar disorder, bipolar disorder, manic phase, major depression with psychotic features and schizoaffective disorder. Issues of diagnostic difficulty and pharmacologic prophylaxis are addressed.

Entities:  

Mesh:

Year:  2004        PMID: 14992306     DOI: 10.1023/b:psaq.0000007564.35985.55

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  14 in total

1.  The clinical efficacy of maintenance electroconvulsive therapy in a patient with a mild mental handicap.

Authors:  B K Puri; A Langa; R M Coleman; I Singh
Journal:  Br J Psychiatry       Date:  1992-11       Impact factor: 9.319

2.  ECT and mental retardation.

Authors:  J M Bebchuk; J Barnhill; K Dawkins
Journal:  Am J Psychiatry       Date:  1996-09       Impact factor: 18.112

3.  Major depression in Down's syndrome.

Authors:  A C Warren; S Holroyd; M F Folstein
Journal:  Br J Psychiatry       Date:  1989-08       Impact factor: 9.319

4.  ECT treatment of an elderly mentally retarded man.

Authors:  M Z Goldstein; M F Jensvold
Journal:  Psychosomatics       Date:  1989       Impact factor: 2.386

5.  Manifestations of depression in people with intellectual disability.

Authors:  G M Marston; D W Perry; A Roy
Journal:  J Intellect Disabil Res       Date:  1997-12

6.  Severe behaviour problems associated with rapid cycling bipolar disorder in two adults with profound mental retardation.

Authors:  M A Lowry; R Sovner
Journal:  J Intellect Disabil Res       Date:  1992-06

7.  Electroconvulsive therapy and major depression in Down's syndrome.

Authors:  A Lazarus; R L Jaffe; W R Dubin
Journal:  J Clin Psychiatry       Date:  1990-10       Impact factor: 4.384

8.  Cotard's syndrome in a mentally handicapped man.

Authors:  A Kearns
Journal:  Br J Psychiatry       Date:  1987-01       Impact factor: 9.319

9.  Dysthymia and mental handicap.

Authors:  J Jancar; I J Gunaratne
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

10.  Posttraumatic stress disorder in persons with developmental disabilities.

Authors:  R Ryan
Journal:  Community Ment Health J       Date:  1994-02
View more
  5 in total

1.  Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: a retrospective study.

Authors:  Angele Consoli; Johan Cohen; Nicolas Bodeau; Vincent Guinchat; Lee Wachtel; David Cohen
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-08-25       Impact factor: 4.785

Review 2.  A review of empirical evidence of somatic treatment options for the MI/DD population.

Authors:  Thaddeus P Ulzen; Richard E Powers
Journal:  Psychiatr Q       Date:  2008-08-23

Review 3.  Diagnosis and treatment of mood disorders in adults with developmental disabilities.

Authors:  Diana J Antonacci; Nadir Attiah
Journal:  Psychiatr Q       Date:  2008-08-23

Review 4.  Diagnosis and treatment of depression in patients with mental retardation.

Authors:  David S Janowsky; John M Davis
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

5.  Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A).

Authors:  Glòria Arqué; Vassiliki Fotaki; David Fernández; María Martínez de Lagrán; Maria L Arbonés; Mara Dierssen
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.